Tuesday, July 15, 2014

Tabalumab at the EULAR 2014 Meeting in Paris


I've already said bye bye to tabalumab a year ago as I had been very disappointed with the data shown during the past two years, but here we still are. Tabalumab (LY2127399) is a human IgG4 monoclonal antibody against B-cell activating factor (BAFF). And there have been two abstracts/posters.

J.S. Smolen and colleagues presented [FRI0326]: "EFFICACY AND SAFETY OF TABALUMAB, AN ANTI-B CELL ACTIVATING FACTOR MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAD AN INADEQUATE RESPONSE TO METHOTREXATE THERAPY: RESULTS FROM A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY". Conclusions: "In this phase 3 study, tabalumab demonstrated no clinical efficacy despite evidence of biologic activity. There were no differences in reports of AEs of interest and no new or unexpected safety findings for RA pts receiving tabalumab."

M. Schiff and colleagues presented [AB0438]: "EFFICACY AND SAFETY OF TABALUMAB, AN ANTI-B CELL ACTIVATING FACTOR MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAD AN INADEQUATE RESPONSE TO TNF-ALPHA INHIBITORS: RESULTS FROM A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY". Conclusions: "In this phase 3 study, tabalumab demonstrated no clinical efficacy despite evidence of biologic activity, suggesting that targeting BAFF may not be a viable therapeutic approach to treating pts with RA. There were no differences in reports of infection or allergic/hypersensitivity events and no new or unexpected safety findings for RA pts receiving tabalumab."

In the case of tabalumab I hate to be proven right: it's bye bye tabalumab!

Link:


No comments:

Post a Comment